{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:58:46Z","timestamp":1793249926838,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-020859"],"award-info":[{"award-number":["INV-020859"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1203429"],"award-info":[{"award-number":["OPP1203429"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1154686"],"award-info":[{"award-number":["OPP1154686"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-008552"],"award-info":[{"award-number":["INV-008552"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.vaccine.2025.126950","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T04:51:36Z","timestamp":1740977496000},"page":"126950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Sabin inactivated polio vaccine upstream process development using fixed-bed bioreactor technology"],"prefix":"10.1016","volume":"53","author":[{"given":"Ahd","family":"Hamidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Willemsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Drugmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nika Z.","family":"Ballmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim","family":"Velthof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Verdurmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Catarina","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochem","family":"Pronk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Palladino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menzo","family":"Havenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Yallop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried A.M.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.126950_bb0005","article-title":"Immunization against poliomyelitis and the challenges to worldwide poliomyelitis eradication","volume":"224(Supplement_4):S398-S404","author":"Modlin","year":"2021","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126950_bb0010","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/pathogens13030224","article-title":"Inactivated poliovirus vaccine: recent developments and the tortuous path to global acceptance","volume":"13","author":"Sutter","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2025.126950_bb0015","unstructured":"GAVI. Hexavalent vaccine programme information. Website: https:\/\/www.gavi.org\/our-support\/guidelines\/hexavalent-vaccine-programme-information (accessed 20-AUG-2024)."},{"key":"10.1016\/j.vaccine.2025.126950_bb0020","series-title":"WHO global action plan","article-title":"WHO global action plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.vaccine.2025.126950_bb0025","first-page":"1","article-title":"Viral vaccine production in cell culture","author":"Auni\u0146\u0161","year":"2009","journal-title":"Encyclopedia of Industrial Biotechnology: Bioprocess, Bioseparation, and Cell Technology"},{"issue":"33","key":"10.1016\/j.vaccine.2025.126950_bb0030","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1016\/j.vaccine.2017.06.003","article-title":"The complexity and cost of vaccine manufacturing \u2013 an overview","volume":"35","author":"Plotkin","year":"2017","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126950_bb0035","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/risa.13557","article-title":"Potential future use, costs, and value of poliovirus vaccines","volume":"41","author":"Thompson","year":"2021","journal-title":"Risk Anal"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126950_bb0040","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/biot.201400388","article-title":"Designing cell lines for viral vaccine production: Where do we stand?","volume":"10","author":"Genzel","year":"2015","journal-title":"Biotechnol J"},{"issue":"41","key":"10.1016\/j.vaccine.2025.126950_bb0045","doi-asserted-by":"crossref","first-page":"7188","DOI":"10.1016\/j.vaccine.2011.05.079","article-title":"Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV","volume":"29","author":"Bakker","year":"2011","journal-title":"Vaccine"},{"issue":"35","key":"10.1016\/j.vaccine.2025.126950_bb0050","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1016\/j.vaccine.2015.03.076","article-title":"sIPV process development for costs reduction","volume":"33","author":"Thomassen","year":"2015","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126950_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083374","article-title":"Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals","volume":"8","author":"Thomassen","year":"2013","journal-title":"PLoS One"},{"issue":"35","key":"10.1016\/j.vaccine.2025.126950_bb0060","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1016\/j.vaccine.2015.04.050","article-title":"Increasing Vero viable cell densities for yellow fever virus production in stirred-tank bioreactors using serum-free medium","volume":"33","author":"Mattos","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126950_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2020.107608","article-title":"Vero cell upstream bioprocess development for the production of viral vectors and vaccines","volume":"44","author":"Kiesslich","year":"2020","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.vaccine.2025.126950_bb0070","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jlp.2014.04.001","article-title":"System safety principles: A multidisciplinary engineering perspective","volume":"29","author":"Saleh","year":"2014","journal-title":"J Loss Prev Process Ind"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2025.126950_bb0075","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1089\/hum.2019.247","article-title":"Benchmarking of scale-X bioreactor system in lentiviral and adenoviral vector production","volume":"31","author":"Leinonen","year":"2020","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2025.126950_bb0080","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jbiotec.2020.01.015","article-title":"Losa JPV-C, G\u00e9linas J-F, Kamen AA: serum-free production of rVSV-ZEBOV in Vero cells: Microcarrier bioreactor versus scale-X\u2122 hydro fixed-bed","volume":"310","author":"Kiesslich","year":"2020","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2025.126950_bb0085","unstructured":"Univercells Technologies. Univercells Technologies products. 2024. Website: https:\/\/www.univercellstech.com\/products\/ (accessed 04-JUL-2024)."},{"key":"10.1016\/j.vaccine.2025.126950_bb0090","series-title":"WHO Technical Report Series","article-title":"51st report: WHO TRS N\u00b0910","author":"World Health Organization","year":"2000"},{"key":"10.1016\/j.vaccine.2025.126950_bb0095","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.procbio.2019.03.010","article-title":"Kinetic model for adherent Vero cell growth and poliovirus production in batch bioreactors","volume":"81","author":"Jiang","year":"2019","journal-title":"Process Biochem"},{"key":"10.1016\/j.vaccine.2025.126950_bb0100","article-title":"Development of an animal component free production process for Sabin inactivated polio vaccine","volume":"12","author":"Suarez-Zuluaga","year":"2022","journal-title":"Vaccine: X"},{"key":"10.1016\/j.vaccine.2025.126950_bb0105","unstructured":"Cytiva. Microcarrier cell culture - Principles and methods. 2021. Website: https:\/\/www.cytivalifesciences.com\/en\/us\/support\/handbooks (accessed 04-JUL-2024)."},{"key":"10.1016\/j.vaccine.2025.126950_bb0110","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1093\/clinids\/6.Supplement_2.S335","article-title":"Inactivated poliovirus vaccine: current production methods and new developments","volume":"6(Supplement_2)","author":"van Wezel","year":"1984","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126950_bb0115","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.biologicals.2009.08.019","article-title":"Substrates WSGoC: Evaluation of cell substrates for the production of biologicals: Revision of WHO recommendations: Report of the WHO study group on cell substrates for the production of biologicals, 22\u201323 April 2009, Bethesda, USA","volume":"38","author":"Knezevic","year":"2010","journal-title":"Biologicals"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126950_bb0120","doi-asserted-by":"crossref","DOI":"10.1186\/s13568-014-0025-z","article-title":"Assessment of packed bed bioreactor systems in the production of viral vaccines","volume":"4","author":"Rajendran","year":"2014","journal-title":"AMB Express"},{"issue":"20","key":"10.1016\/j.vaccine.2025.126950_bb0125","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1016\/j.vaccine.2020.03.041","article-title":"Development of a high-yield live-virus vaccine production platform using a novel fixed-bed bioreactor","volume":"38","author":"Berrie","year":"2020","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126950_bb0130","doi-asserted-by":"crossref","DOI":"10.1002\/biot.202000020","article-title":"Evaluation of the single-use fixed-bed bioreactors in scalable virus production","volume":"16","author":"Lesch","year":"2021","journal-title":"Biotechnol J"},{"key":"10.1016\/j.vaccine.2025.126950_bb0135","first-page":"54","article-title":"Use of membrane technology in the bioprocessing of therapeutic proteins from inclusion bodies of E. Coli","volume":"7","author":"Pattnaik","year":"2009","journal-title":"Bioprocess International"},{"key":"10.1016\/j.vaccine.2025.126950_bb0140","doi-asserted-by":"crossref","first-page":"30","DOI":"10.12665\/J111.Raghunath","article-title":"Best practices for optimization and scale-up of microfiltration TFF processes","volume":"11","author":"Raghunath","year":"2012","journal-title":"Bioprocess J"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126950_bb0145","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1007\/s12010-009-8674-0","article-title":"Rapid screening of serum-free Media for the Growth of adherent Vero cells by using a small-scale and non-invasive tool","volume":"160","author":"Petiot","year":"2009","journal-title":"Appl Biochem Biotechnol"},{"key":"10.1016\/j.vaccine.2025.126950_bb0150","series-title":"Bioreactors for tissue engineering","author":"Chaudhuri","year":"2005"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25002476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25002476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:21:39Z","timestamp":1777537299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25002476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":30,"alternative-id":["S0264410X25002476"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126950","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sabin inactivated polio vaccine upstream process development using fixed-bed bioreactor technology","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126950","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126950"}}